Q&A with Patrick Welch, President & CMO at Bigtincan

MEDIA 7 | September 17, 2019

Patrick Welch, President and CMO at Bigtincan is a top performing senior executive with 22 years’ experience managing, bringing to market and selling innovative software management solutions to various high value market segments.

Patrick is an inspirational executive with a strong track record of building loyal, high-performance teams and successful businesses in the B2B technology space.

MEDIA 7: You’ve an exemplary career growth record with 9 promotions in 14 years. What do you believe is your superpower for being able to achieve the outcome you desire?
PATRICK WELCH: A great wife and family. Also, I’ve been fortunate to be part of some great companies, that have found product market fit in the large, fast growing paradigm shift. It��s really seeing the opportunity in the market, then surrounding yourself with great people, executing and never wavering.

M7: You’ve been quite influential in growing Netegrity from start-up to $100 million+ in annual sales, showing your positive attitude of “growing-with-the-company instead of growing-within-companies.” How is the feeling of witnessing the company rise from scratch to the empire it is today, and what valuable experience have you derived from this?
PW: The journey is amazing, but it’s important to reflect on the ingredients for success. In Netegrity’s case, we had some amazing people, really focused on the enterprise customer, listening and building a roadmap with clients that allowed us to stay ahead of the competition and win big in the market. I also believe you need to create an ecosystem to embrace the customer and fit into their needs. Markets and products have a life span, so it’s crucial to ensure the company is constantly innovating while layering the tech on top.


"Markets and products have a life span, so it’s crucial to ensure the company is constantly innovating while layering the tech on top."

M7: Being an inspirational executive with a record of building loyal, high-performance teams, how do you ensure that passionate, competitive, and driven-to-succeed attitude and team spirit prevails in your team and how well do you believe that communicating effectively up and down can transform any organization into a robust one?
PW: I believe you need to give your teams the opportunity to grow, and they will produce well beyond expectations. This includes providing them with opportunities to take on new challenges and  promotions but also participate in new projects/ventures that they are passionate about. As a leader you need to find great people, listen to where they want to go in their career and help them take the necessary steps towards that goal during the journey and heat of the battle.


M7: You’ve been included in the list of official members of Forbes Communications Council owing to your in-depth knowledge and diverse experience. What are the measures that the council takes to support budding entrepreneurs to thrive and succeed?
PW: It’s really about the community and networking with other CMOs, presidents, CEO, marketers and being able draw on each other’s experiences to push the needle industry-wide. It’s a way to share experiences with like-minded folks and be able derive real value through sharing best practices. With this approach, everyone wins and business performance continues to improve.


"As a leader you need to find great people, listen to where they want to go in their career and help them take the necessary steps towards that goal during the journey and heat of the battle."

M7: What makes Bigtincan stand out as a leading mobile content enablement platform and how is it revolutionizing mobile content enablement along with boosting customer interaction counts?
PW: Bigtincan’s flagship platform, Bigtincan Hub, redefines sales, marketing and service processes to enable teams to work smarter and faster together for optimal results. With sophisticated, AI-driven features and automation that supports each phase of the buying process, Bigtincan Hub enables teams to drive improved business results by delivering a better customer experience. At the same time, Bigtincan Hub enables sales, service and marketing teams to drive the sales process with the best, most successful sales content anywhere, anytime and on any device.

The hallmark of the Bigtincan Hub platform is its intelligent, AI-powered automation. It unifies and automates a broader range of sales, marketing and service tasks to help teams learn faster, sell more, and be more productive every day. Customers of Bigtincan currently leverage more than 100 integrations for a variety of end-user functions in the enterprise.


M7: Patrick, as a child, what did you want to be when you grew up?
PW: A Major League Baseball player. I was a big baseball guy, and really enjoyed playing. While I didn’t end up in the major league, I did play through high school and had some great experiences over the years.

ABOUT BIGTINCAN

Bigtincan (ASX:BTH) helps sales and service teams increase win rates and customer satisfaction. The company’s mobile, AI-powered sales enablement automation platform features the industry’s premier user experience that empowers reps to more effectively engage with customers and prospects and encourages team-wide adoption. In addition to seven of the Fortune 10 companies, leading brands including AT&T, ThermoFisher, Merck, ANZ Bank and others rely on Bigtincan to enhance sales productivity at every customer interaction. With global sales and marketing headquartered in Boston, Bigtincan also has offices across EMEA, Australia and Asia. To discover more about how your organization can benefit from the Bigtincan Hub platform, please visit www.bigtincan.com or follow @bigtincan on Twitter.

More C-Suite on deck

Q&A with Sangram Vajre, Co-founder & Chief Evangelist at Terminus

MEDIA 7 | January 9, 2020

Sangram Vajre, Co-Founder & Chief Evangelist at Terminus is also an author and host of the podcast FlipmyFunnel. He is one of the leading minds in B2B marketing. MEDIA 7: What are you passionate about? SANGRAM VAJRE: Three things: Lead professionally. Grow personally. Love family. M7: Terminus has been recognized as one of Georgia’s 40 fastest-growing companies by ACG Atlanta. What factors contribute to this pace? SV: One of our core values is #OneTeam – which means we think and act as one team and know that if we treat our team right, they will treat our customers amazing. There are no great companies, only great people that make those companies.

Read More

Q&A with Andrea Lechner-Becker, Chief Marketing Officer at LeadMD

MEDIA 7 | December 5, 2019

Andrea Lechner-Becker, Chief Marketing Officer at LeadMD is an experienced Marketing and Sales Executive with a demonstrated history of working in the marketing and advertising industry. Skilled in Business Process, Marketo, Sales, Customer Relationship Management (CRM), and IT Service Management, Andrea is also a strong business development professional and a storyteller. MEDIA 7: What inspired you to get into marketing? ANDREA LECHNER: Frankly, not having better options. I originally attended the University of Wisconsin-La Crosse thinking I’d major in Archaeology. I wanted to be Indiana Jones! But, after visiting the archaeology building – i.e. the cold, dark basement of the science building – where a girl sat to piece together pieces of an old Native American vase, I knew archaeology was not going to be the right path for me. And so, without being good at science and a major in art or art history was unlikely to pay my bills, I decided to go into “business”. I originally registered as a management major, but took my first marketing class and thought it was more interesting and switched my sophomore year. That was pretty much it. I’d never been involved in business classes or DECA in high school – I didn’t really know what to do or what jobs in marketing were even possible. I dumb lucked myself into it really. M7: As a storyteller, do you relate the brand to a story or story to the brand? AL: Both? Neither? I think there are stories in every brand, because there are people working on the brand and people engaging with the brand and people using what the brand creates. People, most often a single person, are at the heart of great stories. You can start with the “point” of the story you’re trying to tell. Say you have a software that help accountants better create reports for board meetings. It’s likely you’ll want to tell a success story about an accountant getting promoted to CFO in part because your software helped better communicate their work product to the board. You could have the idea for that and go looking for that story in your customers. OR, you could hear that story, and say, “That’s amazing!” and share it with customers, partners and internal people. Stories are all around us – the most important thing is to keep your ears and eyes open for finding them.

Read More

Q&A with Ed Breault, Chief Marketing Officer at Aprimo

MEDIA 7 | November 28, 2019

Ed Breault, Chief Marketing Officer at Aprimo is a marketer with over 18 years of industry experience. At Aprimo, Ed is responsible for the global brand and growth which includes all Paid/Owned/Earned media, Brand Experience, Product Marketing, Industry Marketing, Influencer Marketing, Strategic Communications, Content Marketing, Analyst Relations, Alliance Marketing, Public Relations, Events, Demand Generation and Account-Based Marketing. MEDIA 7: What’s your superpower? ED BREAULT: I would say it’s applying the full spectrum of art and science that is required in marketing today. Not just left or right brained, but whole-brained strategy. Being human yet data-driven and really understanding numbers and (the right) metrics to make connections to business drivers. Add storytelling to that, so I can effectively communicate to my team, the CEO and CFO as well as my Board of Directors on those metrics, and connecting all that we are doing in marketing to the mission of the business. Then quickly shifting gears to the art and creative aspects of marketing that are required to engage an audience and tell great commercial stories that take complex concepts and craft them in a way that is interesting for people to pay attention to. I have to be the ultimate point of truth for the brand. M7: At Aprimo, how have marketing leadership roles and responsibilities evolved over the past few years? EB: There are so many dimensions needed by marketing leaders today. There are several elements driving this evolution, it’s the new experience battlefront that is emerging and also marketers themselves driving changes. From a market perspective, there is a clear appetite for disruption and consumers are wanting more experiential elements to their buying experience and interactions with brands. Take a few direct to consumer disruptions like trialing products in-home, purchasing directly from a brand or even wanting to ensure that the producer’s trade practices are in line with the buyer’s or even a regulator’s for that matter. Then we want to try before we buy, and we emotionally care about the supply chain of products. Do we TRUST this brand to do business with them? Behind all of this is a story that needs to be told, and it is those marketers who know their audience well and make connections that will win the commercial game. Back to the marketer, there are so many diverse backgrounds that marketers bring now and I’m really intrigued by those who have unconventional backgrounds because they contribute something uniquely new to the field. I love hearing about the marketer’s journey.

Read More

Q&A with Sangram Vajre, Co-founder & Chief Evangelist at Terminus

MEDIA 7 | January 9, 2020

Sangram Vajre, Co-Founder & Chief Evangelist at Terminus is also an author and host of the podcast FlipmyFunnel. He is one of the leading minds in B2B marketing. MEDIA 7: What are you passionate about? SANGRAM VAJRE: Three things: Lead professionally. Grow personally. Love family. M7: Terminus has been recognized as one of Georgia’s 40 fastest-growing companies by ACG Atlanta. What factors contribute to this pace? SV: One of our core values is #OneTeam – which means we think and act as one team and know that if we treat our team right, they will treat our customers amazing. There are no great companies, only great people that make those companies.

Read More

Q&A with Andrea Lechner-Becker, Chief Marketing Officer at LeadMD

MEDIA 7 | December 5, 2019

Andrea Lechner-Becker, Chief Marketing Officer at LeadMD is an experienced Marketing and Sales Executive with a demonstrated history of working in the marketing and advertising industry. Skilled in Business Process, Marketo, Sales, Customer Relationship Management (CRM), and IT Service Management, Andrea is also a strong business development professional and a storyteller. MEDIA 7: What inspired you to get into marketing? ANDREA LECHNER: Frankly, not having better options. I originally attended the University of Wisconsin-La Crosse thinking I’d major in Archaeology. I wanted to be Indiana Jones! But, after visiting the archaeology building – i.e. the cold, dark basement of the science building – where a girl sat to piece together pieces of an old Native American vase, I knew archaeology was not going to be the right path for me. And so, without being good at science and a major in art or art history was unlikely to pay my bills, I decided to go into “business”. I originally registered as a management major, but took my first marketing class and thought it was more interesting and switched my sophomore year. That was pretty much it. I’d never been involved in business classes or DECA in high school – I didn’t really know what to do or what jobs in marketing were even possible. I dumb lucked myself into it really. M7: As a storyteller, do you relate the brand to a story or story to the brand? AL: Both? Neither? I think there are stories in every brand, because there are people working on the brand and people engaging with the brand and people using what the brand creates. People, most often a single person, are at the heart of great stories. You can start with the “point” of the story you’re trying to tell. Say you have a software that help accountants better create reports for board meetings. It’s likely you’ll want to tell a success story about an accountant getting promoted to CFO in part because your software helped better communicate their work product to the board. You could have the idea for that and go looking for that story in your customers. OR, you could hear that story, and say, “That’s amazing!” and share it with customers, partners and internal people. Stories are all around us – the most important thing is to keep your ears and eyes open for finding them.

Read More

Q&A with Ed Breault, Chief Marketing Officer at Aprimo

MEDIA 7 | November 28, 2019

Ed Breault, Chief Marketing Officer at Aprimo is a marketer with over 18 years of industry experience. At Aprimo, Ed is responsible for the global brand and growth which includes all Paid/Owned/Earned media, Brand Experience, Product Marketing, Industry Marketing, Influencer Marketing, Strategic Communications, Content Marketing, Analyst Relations, Alliance Marketing, Public Relations, Events, Demand Generation and Account-Based Marketing. MEDIA 7: What’s your superpower? ED BREAULT: I would say it’s applying the full spectrum of art and science that is required in marketing today. Not just left or right brained, but whole-brained strategy. Being human yet data-driven and really understanding numbers and (the right) metrics to make connections to business drivers. Add storytelling to that, so I can effectively communicate to my team, the CEO and CFO as well as my Board of Directors on those metrics, and connecting all that we are doing in marketing to the mission of the business. Then quickly shifting gears to the art and creative aspects of marketing that are required to engage an audience and tell great commercial stories that take complex concepts and craft them in a way that is interesting for people to pay attention to. I have to be the ultimate point of truth for the brand. M7: At Aprimo, how have marketing leadership roles and responsibilities evolved over the past few years? EB: There are so many dimensions needed by marketing leaders today. There are several elements driving this evolution, it’s the new experience battlefront that is emerging and also marketers themselves driving changes. From a market perspective, there is a clear appetite for disruption and consumers are wanting more experiential elements to their buying experience and interactions with brands. Take a few direct to consumer disruptions like trialing products in-home, purchasing directly from a brand or even wanting to ensure that the producer’s trade practices are in line with the buyer’s or even a regulator’s for that matter. Then we want to try before we buy, and we emotionally care about the supply chain of products. Do we TRUST this brand to do business with them? Behind all of this is a story that needs to be told, and it is those marketers who know their audience well and make connections that will win the commercial game. Back to the marketer, there are so many diverse backgrounds that marketers bring now and I’m really intrigued by those who have unconventional backgrounds because they contribute something uniquely new to the field. I love hearing about the marketer’s journey.

Read More

Related News

INDUSTRIAL IMPACT

Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals

Sirona Biochem Corp. | November 24, 2022

Sirona Biochem Corp. announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals have signed an expanded, international partnership agreement to collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunities currently in due diligence. Wanbang and Sirona initially signed a licensing agreement for TFC-039, whereby Wanbang obtained the rights to develop the compound as a diabetes treatment in China and Sirona retained the global rights. Sirona has since been in discussions with animal health companies to advance TFC-039 as a treatment for diabetes and chronic kidney disease in companion animals. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication as opposed to the traditional method of daily insulin injections. More recently, Sirona has entered into due diligence with a large pharmaceutical company with a regional interest in developing the compound for human diabetes. Together, Sirona and Wanbang share extensive knowledge and scientific results of TFC-039. Partnering will significantly increase the speed to third-party partnerships and commercialization. The shared data spans over 12 years of research and development, and includes in vitro and in vivo preclinical work, multiple clinical studies, advanced manufacturing process development and the ability to commercially manufacture TFC-039. “We have a long-standing relationship with Wanbang and are excited to combine our two companies’ expertise to license TFC-039. Wanbang has invested millions of dollars into the clinical stage research and development of the manufacturing processes for TFC-039. These pieces of data are critical to large organizations and will greatly increase the opportunities to move forward. The probability of a successful licensing agreement has been made much stronger by leveraging our alliance with Wanbang. We have had a successful year building Sirona’s pipeline, with positive movement on all projects and we’re looking forward to continuing this success with our SGLT2 inhibitor as well as our antiviral and anti-aging projects in 2023.” Dr. Howard Verrico, CEO About Wanbang Biopharmaceuticals and Fosun Pharmaceuticals Wanbang Biopharmaceuticals develops, manufactures, and markets drugs with indications for chronic disease treatment, antibiotics, and other endocrine diseases in China. Founded in 1981, the company is headquartered in Xuzhou, China, and is a subsidiary of Shanghai Fosun Pharmaceutical Group. Fosun is a leader in the pharmaceutical industry and is regarded as one of the top five domestic pharmaceutical companies in China. About Sirona Biochem Corp. Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants.

Read More

RESEARCH, INDUSTRY OUTLOOK

BigHat Biosciences Announces Research Collaboration with Merck

BigHat Biosciences, Inc. | November 30, 2022

BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs. BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better biophysical properties. This approach could help reduce the difficulty of optimizing antibodies and other therapeutic proteins. Under the collaboration, BigHat and Merck will collaborate to optimize up to three proteins by leveraging BigHat’s platform to synthesize, express, purify, and characterize molecules. Mark DePristo, co-founder and CEO of BigHat, continued, "We are thrilled to be collaborating with Merck's world-class drug development teams to design safer, more effective antibodies for these important therapeutic programs.” The teams have initiated work on the first program and are looking forward to using the power of the complementary skills sets within each research team to generate high-quality lead antibodies. “We are excited to begin this collaboration to advance next-generation antibody therapeutics to patients,” said Elizabeth Schwarzbach, BigHat’s Chief Business Officer. "This agreement with Merck brings us a major step closer to our goal of 3-5 deep collaborations with leading biopharmas to complement our internal therapeutic pipeline." “This agreement with BigHat expands Merck’s strategy of applying AI/ML across our drug discovery capabilities. We look forward to working with the team to leverage BigHat’s technology and expertise in enabling molecular design of novel biologic candidates.” Juan Alvarez, vice president of Biologics Discovery, Merck Research Laboratories About BigHat Biosciences, Inc. BigHat Biosciences is designing safer, more effective antibody therapies for patients using machine learning and synthetic biology. BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies. They apply these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is a Series B biotech outside San Francisco with a team-oriented, inclusive, and family-friendly culture. BigHat’s broad pipeline of wholly-owned and partnered therapeutic programs span many disparate indications with high unmet need, such as cancer, inflammation, and infectious disease. BigHat has raised over $100M from top investors, including Section 32, a16z, and 8VC.

Read More

INDUSTRIAL IMPACT

Sintalica Bioscience Announces Key Approval Milestones from the Italian Health Authority

Sintalica Bioscience | November 24, 2022

Sintalica Bioscience Corp. a psychedelic drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has received, through the University of Messinathe following authorizations from the Italian Ministry of Health pertaining to its drug development program Synthesis and detention of Schedule I drugs - Psilocybin, Psilocin and other derived tryptamines Cultivation of Psilocybe mushrooms and extraction of tryptamines Positive opinion for the initiation of safety and efficacy testing This combination of authorizations are unique in Europe and will allow Sintalica to pursue its full research and development and clinical program at the University’s laboratory and related facilities. Sintalica’s approach to psychedelic drug discovery focuses on minimizing hallucinogenic effects while enhancing the psychedelic molecule's strong anti-inflammatory properties. Sintalica’s research and drug development program is focused on neurodegenerative disorders, including SCI-Induced Chronic Neuropathic Pain (Spinal Cord Injury), Fibromyalgia, and Inflammation. Sintalica has filed three provisional patents for proprietary psychedelic molecules with claims of improved stability, efficacy and bioavailability. The molecules are being produced in the University’s state-of-the-art laboratories, and will be tested for safety and efficacy toward target indications. Sintalica has an exclusive research partnership with leading Italian research institutes, including the University of Messina and the University of Niccolò Cusano of Rome. Sintalica’s scientific team comprises world-leading scientists in chemistry, pharmacology, biotechnology and neurodegenerative diseases. “These authorizations are critical to Sintalica’s ongoing drug discovery program. We are confident our non-hallucinogenic psychedelic molecules can lead to breakthrough treatments for neuroinflammatory diseases affecting millions of patients worldwide,” Bruce Linton, Chairman and Co-Founder of Sintalica “Today, we mark the final development phase for this important project. It is the culmination of more than one year of teamwork and planning by Sintalica and the University of Messina, in collaboration with Niccolò Cusano University of Rome, that will result in more efficient and more productive organic and biotech synthesis, cultivation, delivery and in vivo trials of psychedelic drugs under one roof,” said Prof. Salvatore Cuzzocrea, Rector of the University of Messina. ABOUT SINTALICA Sintalica Bioscience Corp. is a Canadian drug discovery company operating through its Italian subsidiary focused on using psychedelics to create breakthrough treatments for neuroinflammatory disorders. Sintalica has filed three provisional patents for proprietary psychedelic molecules with improved stability and safety profiles, reduced hallucinogenic effects, and enhanced bioavailability.

Read More

INDUSTRIAL IMPACT

Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals

Sirona Biochem Corp. | November 24, 2022

Sirona Biochem Corp. announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals have signed an expanded, international partnership agreement to collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunities currently in due diligence. Wanbang and Sirona initially signed a licensing agreement for TFC-039, whereby Wanbang obtained the rights to develop the compound as a diabetes treatment in China and Sirona retained the global rights. Sirona has since been in discussions with animal health companies to advance TFC-039 as a treatment for diabetes and chronic kidney disease in companion animals. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication as opposed to the traditional method of daily insulin injections. More recently, Sirona has entered into due diligence with a large pharmaceutical company with a regional interest in developing the compound for human diabetes. Together, Sirona and Wanbang share extensive knowledge and scientific results of TFC-039. Partnering will significantly increase the speed to third-party partnerships and commercialization. The shared data spans over 12 years of research and development, and includes in vitro and in vivo preclinical work, multiple clinical studies, advanced manufacturing process development and the ability to commercially manufacture TFC-039. “We have a long-standing relationship with Wanbang and are excited to combine our two companies’ expertise to license TFC-039. Wanbang has invested millions of dollars into the clinical stage research and development of the manufacturing processes for TFC-039. These pieces of data are critical to large organizations and will greatly increase the opportunities to move forward. The probability of a successful licensing agreement has been made much stronger by leveraging our alliance with Wanbang. We have had a successful year building Sirona’s pipeline, with positive movement on all projects and we’re looking forward to continuing this success with our SGLT2 inhibitor as well as our antiviral and anti-aging projects in 2023.” Dr. Howard Verrico, CEO About Wanbang Biopharmaceuticals and Fosun Pharmaceuticals Wanbang Biopharmaceuticals develops, manufactures, and markets drugs with indications for chronic disease treatment, antibiotics, and other endocrine diseases in China. Founded in 1981, the company is headquartered in Xuzhou, China, and is a subsidiary of Shanghai Fosun Pharmaceutical Group. Fosun is a leader in the pharmaceutical industry and is regarded as one of the top five domestic pharmaceutical companies in China. About Sirona Biochem Corp. Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants.

Read More

RESEARCH, INDUSTRY OUTLOOK

BigHat Biosciences Announces Research Collaboration with Merck

BigHat Biosciences, Inc. | November 30, 2022

BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs. BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better biophysical properties. This approach could help reduce the difficulty of optimizing antibodies and other therapeutic proteins. Under the collaboration, BigHat and Merck will collaborate to optimize up to three proteins by leveraging BigHat’s platform to synthesize, express, purify, and characterize molecules. Mark DePristo, co-founder and CEO of BigHat, continued, "We are thrilled to be collaborating with Merck's world-class drug development teams to design safer, more effective antibodies for these important therapeutic programs.” The teams have initiated work on the first program and are looking forward to using the power of the complementary skills sets within each research team to generate high-quality lead antibodies. “We are excited to begin this collaboration to advance next-generation antibody therapeutics to patients,” said Elizabeth Schwarzbach, BigHat’s Chief Business Officer. "This agreement with Merck brings us a major step closer to our goal of 3-5 deep collaborations with leading biopharmas to complement our internal therapeutic pipeline." “This agreement with BigHat expands Merck’s strategy of applying AI/ML across our drug discovery capabilities. We look forward to working with the team to leverage BigHat’s technology and expertise in enabling molecular design of novel biologic candidates.” Juan Alvarez, vice president of Biologics Discovery, Merck Research Laboratories About BigHat Biosciences, Inc. BigHat Biosciences is designing safer, more effective antibody therapies for patients using machine learning and synthetic biology. BigHat integrates a wet lab for high-speed characterization with machine learning technologies to guide the search for better antibodies. They apply these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is a Series B biotech outside San Francisco with a team-oriented, inclusive, and family-friendly culture. BigHat’s broad pipeline of wholly-owned and partnered therapeutic programs span many disparate indications with high unmet need, such as cancer, inflammation, and infectious disease. BigHat has raised over $100M from top investors, including Section 32, a16z, and 8VC.

Read More

INDUSTRIAL IMPACT

Sintalica Bioscience Announces Key Approval Milestones from the Italian Health Authority

Sintalica Bioscience | November 24, 2022

Sintalica Bioscience Corp. a psychedelic drug discovery company focused on breakthrough treatments for neuroinflammatory disorders, today announced that the Company has received, through the University of Messinathe following authorizations from the Italian Ministry of Health pertaining to its drug development program Synthesis and detention of Schedule I drugs - Psilocybin, Psilocin and other derived tryptamines Cultivation of Psilocybe mushrooms and extraction of tryptamines Positive opinion for the initiation of safety and efficacy testing This combination of authorizations are unique in Europe and will allow Sintalica to pursue its full research and development and clinical program at the University’s laboratory and related facilities. Sintalica’s approach to psychedelic drug discovery focuses on minimizing hallucinogenic effects while enhancing the psychedelic molecule's strong anti-inflammatory properties. Sintalica’s research and drug development program is focused on neurodegenerative disorders, including SCI-Induced Chronic Neuropathic Pain (Spinal Cord Injury), Fibromyalgia, and Inflammation. Sintalica has filed three provisional patents for proprietary psychedelic molecules with claims of improved stability, efficacy and bioavailability. The molecules are being produced in the University’s state-of-the-art laboratories, and will be tested for safety and efficacy toward target indications. Sintalica has an exclusive research partnership with leading Italian research institutes, including the University of Messina and the University of Niccolò Cusano of Rome. Sintalica’s scientific team comprises world-leading scientists in chemistry, pharmacology, biotechnology and neurodegenerative diseases. “These authorizations are critical to Sintalica’s ongoing drug discovery program. We are confident our non-hallucinogenic psychedelic molecules can lead to breakthrough treatments for neuroinflammatory diseases affecting millions of patients worldwide,” Bruce Linton, Chairman and Co-Founder of Sintalica “Today, we mark the final development phase for this important project. It is the culmination of more than one year of teamwork and planning by Sintalica and the University of Messina, in collaboration with Niccolò Cusano University of Rome, that will result in more efficient and more productive organic and biotech synthesis, cultivation, delivery and in vivo trials of psychedelic drugs under one roof,” said Prof. Salvatore Cuzzocrea, Rector of the University of Messina. ABOUT SINTALICA Sintalica Bioscience Corp. is a Canadian drug discovery company operating through its Italian subsidiary focused on using psychedelics to create breakthrough treatments for neuroinflammatory disorders. Sintalica has filed three provisional patents for proprietary psychedelic molecules with improved stability and safety profiles, reduced hallucinogenic effects, and enhanced bioavailability.

Read More

Spotlight

Bigtincan

Bigtincan

Bigtincan (ASX:BTH) helps sales and service teams increase win rates and customer satisfaction. The company’s mobile, AI-powered sales enablement automation platform features the industry’s premier user experience that empowers reps to more effectively engage with customers and prospects and encoura...

Events

Resources